drugset / Trial / NCT01568047

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

NCT01568047

Phase 2 Completed 40 enrolled Bial - Portela C S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor.

Timeline

Start
2010-02
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule 100 mg
Subject Opicapone Small molecule 5 mg
Subject Opicapone Small molecule 15 mg
Subject Opicapone Small molecule 30 mg
Background Benzerazide Unknown 25 mg
Background Carbidopa Unknown 25 mg

Indications